Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series

• Published in: Critical care (London, England) Vol. 24; no. 1; p. 392
• Main Authors: Doi, Kent, Ikeda, Mahoko, Hayase, Naoki, Moriya, Kyoji, Morimura, Naoto
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 03.07.2020; BioMed Central; BMC
• Subjects: Aged; Amides - therapeutic use; Benzamidines; Combination drug therapy; Coronavirus Infections - drug therapy; Coronaviruses; COVID-19; COVID-19 Drug Treatment; Critical care; Critical Illness; Critically ill persons; Drug therapy; Drug Therapy, Combination; Favipiravir; Female; Guanidines - therapeutic use; Humans; Influenza; Intensive care; Male; Methods; Middle Aged; Middle East respiratory syndrome; Mortality; Patients; Protease inhibitors; Pyrazines - therapeutic use; Research Letter; Respiratory diseases; Severe acute respiratory syndrome coronavirus 2; Treatment Outcome; Ventilators; Viruses; Japan; Middle East
• ISSN: 1364-8535; 1466-609X; 1364-8535; 1366-609X
• DOI: 10.1186/s13054-020-03078-z

Eleven adults with reverse transcriptase polymerase chain reaction-confirmed SARS-CoV-2 infection were admitted to the intensive care unit (ICU) at The University of Tokyo Hospital between April 6 and April 21, 2020, and treated with nafamostat mesylate in combination with favipiravir. [...]nafamostat mesylate therapy in combination with favipiravir may allow blockade of virus entry and replication, as well as inhibition of pathogenic host response, i.e., hyper-coagulopathy. Mechanical ventilation SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2 TMPRSS2: Transmembrane protease serine 2 VV-ECMO: Venovenous extracorporeal membrane oxygenation 1.